Results Of Systemic Therapy Research Articles

AB008. Results of systemic therapy and surgery for primary mediastinal seminoma

AB008. Results of systemic therapy and surgery for primary mediastinal seminoma

Ultrasound-Guided Laser Therapy for Rosacea (Clinical Observation)

The article describes a clinical case of high-resolution ultrasound (US) diagnostics of changes in the intensity of blood supply to the dermis of a patient with rosacea at different stages of treatment and early visualization of exacerbation. The presented clinical case demonstrates the possibilities of ultrasound in planning the treatment of rosacea, objective assessment of the results of systemic therapy and laser correction, personalization of the protocol, taking into account the clinical findings and instrumental methods of examination.

Correlations between colorectal cancer biomarkers

This short review describes the main biomarkers used in research and clinical practice for colon cancer. There are several categories of biomarkers, depending on the substrate they represent or the method of harvesting. We will discuss about genetic biomarkers like microsatellite instability, KRAS, BRAF etc. Blood-based biomarkers available to monitor patients with colorectal cancer are represented by CEA and carbohydrate antigen 19-9 (CA19-9). CEA, a high molecular weight glycoprotein, is found in embryonic tissue and colorectal malignancies. We also present the stool markers. These markers are useful for screening patients at risk to develop colon cancer. The markers are also used to monitor the progression of the disease and the results of systemic therapy.

Chasing Mutations in the Epidermal Growth Factor in Lung Cancer

Non–small-cell lung cancer is the leading cause of death from cancer in men and women in the United States, and worldwide it kills more than 1 million people annually. Approximately two thirds of patients with non–small-cell lung cancer present with locally advanced or metastatic disease that requires systemic therapy in addition to surgery or radiation therapy. The good news is that the results of systemic therapy are improving: chemotherapy prolongs survival and improves the quality of life for patients with non–small-cell lung cancer. The bad news is that systemic therapy is still woefully inadequate: only 30 to 40 percent of . . .

Transplantation of human benign hyperplastic prostate tissue into nude mice: first results of systemic therapy.

Xenografts of human benign hyperplastic prostate tissue (BPH) have been established as a model for the investigation of the etiology of BPH. In this paper it is our aim to answer the question of whether this model is useful for the established therapy of the disease. Additionally we try to evaluate the value of a commonly used plant extract for the therapy of BPH. Is there any influence of the extract from Sabal serrulatum on the BPH tissue in our model? Human BPH tissue from 2 patients was transplanted into athymic nude mice and treated with three different regimens. Animals of group I did not receive any treatment and served as control, in groups II and III the tissue was stimulated by application of silicone tubes containing crystalline 5 alpha-dihydrotestosterone and estradiol. Animals of group II additionally were treated orally with the lipophilic extract of S. serrulatum (contained in Prostagutt N), which is commonly used for the treatment of BPH clinically. Significant inhibition of tissue growth was observed in group III when compared to group II. In group I (control) atrophy of the graft was observed as expected. However, histologically no differences were visible between groups II and III. Our experiment shows a significant growth-inhibiting effect of the plant extract for human BPH tissue in our model (p less than 0.05). We conclude that the nude mouse model can be useful for the evaluation of systemic therapy modalities of human BPH and that the plant extract may have a certain value for clinical treatment, which is not only due to subjective criteria.

Influence of adjuvant chemotherapy for operable breast cancer on results of treatment at relapse.

The influence of adjuvant chemotherapy (ACT) for operable breast cancer on the results of systemic therapy at relapse was retrospectively studied in 62 patients with recurrent disease. 32 had been treated with ACT [ACT (+) group] and the others had not [ACT (-) group]. The response rate (CR + PR) to the first treatment was 22% in the ACT (+) group and 43% in ACT (-) group. It is suggested that relapsing patients with a history of ACT respond poorly to the treatment as compared to those not receiving it.